Eric Berger
파트너,
Eric
Eric Berger is an expert in Bain’s Healthcare and Private Equity practices with more than 10 years of consulting experience.
Eric advises clients across a range of industries, with a focus in private equity funds as well as healthcare payers and services and biotech / pharma. He has additional experience in industrial goods and services and consumer packaged goods.
He holds expertise in topics related to commercial due diligence, business unit strategy, operating model, organization design, pricing, brand strategy and mergers & acquisitions.
Prior to joining Bain in 2011, Eric worked for a small consulting firm in Boston focused on the pharmaceutical, biotech and medical device industries. Previously, he was a researcher in organic chemistry at Harvard University. Eric has published in Science and the Journal of the American Chemical Society and was awarded a grant from the Howard Hughes Medical Institute and the Jean Dreyfus Boissevain scholarship.
Eric earned an MBA from MIT Sloan School of Management. He holds a BA cum laude and MA in chemistry from Harvard University.
Recent Insights
- “New report from Bain & Company and KLAS Research finds that software investments remain a top priority for healthcare providers,” Press release, 2022년10월17일
- “2022 Healthcare Provider IT Report: Post-Pandemic Investment Priorities,” Report, 2022년10월17일
- “Primary Care 2030: Innovative Models Transform the Landscape ,” Brief, 2022년7월11일
- “Healthcare Private Equity in North America: Macro Trends Broaden Investment Opportunities ,” Report, 2022년3월15일
- “Biopharma: Traditional Pharma Services Lead the Way ,” Report, 2022년3월15일